SHPH

+ Watchlist + Portfolio

Shuttle Pharmaceuticals Holdings, Inc.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $3.76
52-Week Range: $2.58 – $55.90
Market Cap: $2.17M
P/E (TTM): 37.10
EPS (TTM): 0.10
Dividend Yield: —

Advanced Metrics

Price/Book: 0.62
PEG Ratio: —
Return on Equity: -326.36%
Return on Assets: -81.65%
Gross Margin: 0.00%
Operating Margin: 0.00%
Profit Margin: 0.00%
Current Ratio: 0.30
Debt/Equity: 0.06
Total Debt: $214.01K
Free Cash Flow: $740.94K
Revenue Growth: —
Earnings Growth: —
Enterprise Value: $1.29M

SHPH Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$0.00	$0.00	$0.00	$0.00
Research & Development	$1.05M	$3.52M	$3.62M	$4.05M
Selling, General & Admin	$1.30M	$2.38M	$4.08M	$7.86M
Operating Expenses	$2.34M	$5.89M	$7.70M	$11.92M
Operating Income	-$2.34M	-$5.89M	-$7.70M	-$11.92M
EBITDA	-$4.51M	-$3.99M	-$7.78M	-$11.36M
Pretax Income	-$5.00M	-$6.59M	-$9.14M	-$11.72M
Income Tax	$0.00	—	—	—
Net Income	-$5.00M	-$6.59M	-$9.14M	-$11.72M
Diluted EPS	-1260.00	-882.50	-826.00	-71.60
Diluted Shares	5350	7465	11549	163792

SHPH Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$8.42M	$2.58M	$1.92M	$334.00K
Receivables	$0.00	$14.90K	$0.00	—
Current Assets	$8.58M	$5.59M	$2.21M	$502.91K
Total Assets	$8.65M	$5.95M	$2.51M	$10.48M
Current Liabilities	$975.68K	$1.04M	$1.53M	$7.97M
Long-Term Debt	—	$135.09K	—	—
Total Debt	$748.30K	$1.09M	$1.17M	$232.15K
Total Liabilities	$975.68K	$1.90M	$1.80M	$8.22M
Retained Earnings	-$18.84M	-$25.43M	-$34.58M	-$46.30M
Shareholders' Equity	$7.68M	$4.06M	$709.15K	$2.25M
Working Capital	$7.60M	$4.55M	$677.15K	-$7.46M

SHPH Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$2.67M	-$5.58M	-$7.33M	-$9.48M
Capital Expenditure	—	-$19.05K	—	-$3.06M
Free Cash Flow	-$2.67M	-$5.60M	-$7.33M	-$12.54M
Depreciation & Amortisation	$5.97K	$6.81K	$5.46K	$290.11K
Stock-Based Compensation	$237.55K	$181.96K	$259.74K	$932.97K
Investing Cash Flow	$0.00	-$2.83M	$2.92M	-$3.06M
Financing Cash Flow	$10.58M	$2.57M	$3.76M	$10.95M
Dividends Paid	—	—	$0.00	$0.00
Net Change in Cash	$7.91M	-$5.84M	-$656.27K	-$1.59M

SHPH Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Revenue	$0.00	$0.00	$0.00	$0.00	$0.00
Research & Development	$1.57M	$1.03M	$943.48K	$511.88K	$267.24K
Selling, General & Admin	$1.38M	$2.88M	$1.32M	$2.28M	$1.95M
Operating Expenses	$2.95M	$3.91M	$2.27M	$2.79M	$2.22M
Operating Income	-$2.95M	-$3.91M	-$2.27M	-$2.79M	-$2.22M
EBITDA	-$3.04M	-$3.68M	-$2.33M	-$2.31M	-$1.51M
Pretax Income	-$3.05M	-$3.71M	-$2.35M	-$2.61M	-$2.15M
Net Income	-$3.05M	-$3.71M	-$2.35M	-$2.61M	-$2.15M
Diluted EPS	-76.00	-32.90	-10.50	—	-4.30
Diluted Shares	40195	112605	223365	—	503156

SHPH Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Cash & Equivalents	$4.51M	$4.82M	$2.09M	$334.00K	$1.09M
Current Assets	$4.96M	$5.19M	$3.27M	$502.91K	$2.46M
Total Assets	$5.31M	$5.50M	$3.54M	$10.48M	$11.81M
Current Liabilities	$1.78M	$1.69M	$1.96M	$7.97M	$8.31M
Total Debt	$1.10M	$712.98K	$667.33K	$232.15K	$214.01K
Total Liabilities	$2.02M	$1.90M	$2.15M	$8.22M	$8.46M
Retained Earnings	-$37.63M	-$41.34M	-$43.68M	-$46.30M	-$48.45M
Shareholders' Equity	$3.29M	$3.61M	$1.39M	$2.25M	$3.35M
Working Capital	$3.18M	$3.50M	$1.30M	-$7.46M	-$5.84M

SHPH Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Operating Cash Flow	-$2.53M	-$3.36M	-$2.63M	-$973.01K	-$2.42M
Capital Expenditure	—	—	—	—	-$36.00K
Free Cash Flow	-$2.53M	-$3.36M	-$2.63M	-$4.03M	-$2.45M
Depreciation & Amortisation	$1.01K	-$979.00	$1.01K	$289.07K	$633.34K
Stock-Based Compensation	$537.05K	$46.85K	$134.32K	$214.75K	$35.02K
Investing Cash Flow	$0.00	$0.00	$0.00	-$3.06M	-$36.00K
Financing Cash Flow	$5.12M	$3.66M	-$96.38K	$2.27M	$3.21M
Dividends Paid	$0.00	$0.00	$0.00	$0.00	$0.00
Net Change in Cash	$2.59M	$305.06K	-$2.72M	-$1.76M	$755.94K

Market Snapshot

About

Shuttle Pharmaceuticals Holdings is a clinical-stage pharmaceutical company developing novel therapies to cure cancer. The company focuses on improving outcomes for cancer patients treated with radiation therapy. Shuttle Pharmaceuticals is advancing multiple drug candidates through preclinical and clinical development.